“Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma” has been added to your cart. View cart

Article: P31 Approach of an IgM monoclonal gammopathy: clinical relevance of the MYD88 L265P mutation

€3.03

SKU: product-article-14923 Category: General

Description
Reviews (0)

Description

P31 Approach of an IgM monoclonal gammopathy: clinical relevance of the MYD88 L265P mutation

Reviews

There are no reviews yet.

Be the first to review “Article: P31 Approach of an IgM monoclonal gammopathy: clinical relevance of the MYD88 L265P mutation”

You must be logged in to post a review.

Top

Article: P31 Approach of an IgM monoclonal gammopathy: clinical relevance of the MYD88 L265P mutation

Description

Reviews

Related products

Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer

Article: Calendar of events

Article: Highlights in digestive oncology

Article: Highlights in digestive oncology